NASDAQ:SGRYSurgery Partners Stock Price, Forecast & News

$14.97

+0.29 (+1.98 %)

(As of 05/26/2020 01:14 PM ET)

Add

Compare

Today's Range

$14.34

Now: $14.97▼

$15.37

50-Day Range

$4.80

MA: $9.80▼

$14.04

52-Week Range

$4.00

Now: $14.97▼

$19.74

Volume56,338 shs

Average Volume973,444 shs

Market Capitalization$756.28 million

P/E RatioN/A

Dividend YieldN/A

Beta3.45

Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and related services in the United States. The company operates through three segments: Surgical Facility Services, Ancillary Services, and Optical Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and a suite of ancillary services, which consist of a diagnostic laboratory, multi-specialty physician practices, urgent care facilities, anesthesia services, and optical services. It also operates optical laboratory that manufactures eyewear. As of December 31, 2018, the company owned or operated a portfolio of 123 surgical facilities, including 108 ambulatory surgical centers and 15 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

Beat the Market (BTM) Rank^™

1.4 Analyst's Opinion

Consensus Rating
Surgery Partners has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.50, Surgery Partners has a potential upside of 3.5% from its current price of $14.97.
Amount of Analyst Coverage
Surgery Partners has only been the subject of 3 research reports in the past 90 days.

2.2 Community Rank

Outperform Votes
Surgery Partners has received 245 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Surgery Partners has received 319 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Surgery Partners has received 56.56% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Surgery Partners and other stocks. Vote “Outperform” if you believe SGRY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SGRY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Surgery Partners does not currently pay a dividend.
Dividend Growth
Surgery Partners does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Surgery Partners insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.80% of the stock of Surgery Partners is held by insiders.
Percentage Held by Institutions
93.05% of the stock of Surgery Partners is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Surgery Partners are expected to grow in the coming year, from ($1.34) to ($0.43) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Surgery Partners is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Surgery Partners is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Surgery Partners has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.17 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry General medical & surgical hospitals

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SGRY

Previous Symbol

CUSIPN/A

CIK1638833

Webwww.surgerypartners.com

Phone615-234-5900

Debt

Debt-to-Equity Ratio2.84

Current Ratio1.49

Quick Ratio1.37

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.83 billion

Price / Sales0.41

Cash Flow$0.54 per share

Price / Cash Flow27.75

Book Value$19.67 per share

Price / Book0.76

Profitability

EPS (Most Recent Fiscal Year)($1.10)

Net Income$-74,800,000.00

Net Margins-4.38%

Return on Equity-2.21%

Return on Assets-0.44%

Miscellaneous

Employees9,600

Outstanding Shares50,520,000

Market Cap$756.28 million

Next Earnings Date8/5/2020 (Estimated)

OptionableOptionable

Receive SGRY News and Ratings via Email

Sign-up to receive the latest news and ratings for SGRY and its competitors with MarketBeat's FREE daily newsletter.

Surgery Partners (NASDAQ:SGRY) Frequently Asked Questions

How has Surgery Partners' stock been impacted by COVID-19 (Coronavirus)?

Surgery Partners' stock was trading at $8.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SGRY stock has increased by 69.0% and is now trading at $14.97. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Surgery Partners?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surgery Partners in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Surgery Partners.

When is Surgery Partners' next earnings date?

Surgery Partners is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Surgery Partners.

How were Surgery Partners' earnings last quarter?

Surgery Partners Inc (NASDAQ:SGRY) posted its quarterly earnings data on Monday, May, 11th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.28. The firm earned $441 million during the quarter, compared to analysts' expectations of $377.50 million. Surgery Partners had a negative return on equity of 2.21% and a negative net margin of 4.38%. View Surgery Partners' earnings history.

What price target have analysts set for SGRY?

4 brokerages have issued 1 year target prices for Surgery Partners' shares. Their forecasts range from $14.00 to $19.00. On average, they anticipate Surgery Partners' share price to reach $15.50 in the next year. This suggests a possible upside of 3.5% from the stock's current price. View analysts' price targets for Surgery Partners.

Has Surgery Partners been receiving favorable news coverage?

News headlines about SGRY stock have trended positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Surgery Partners earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutSurgery Partners.

Are investors shorting Surgery Partners?

Surgery Partners saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,960,000 shares, an increase of 6.9% from the April 30th total of 2,770,000 shares. Based on an average daily volume of 981,200 shares, the days-to-cover ratio is currently 3.0 days. Currently, 12.9% of the shares of the company are short sold. View Surgery Partners' Current Options Chain.

Who are some of Surgery Partners' key competitors?

Some companies that are related to Surgery Partners include Dechra Pharmaceuticals (DPH), Omnicell (OMCL), Denali Therapeutics (DNLI), Amarin (AMRN), Fate Therapeutics (FATE), Alkermes (ALKS), Novavax (NVAX), Alector (ALEC), Intercept Pharmaceuticals (ICPT), Integer (ITGR), Taro Pharmaceutical Industries (TARO), Apellis Pharmaceuticals (APLS), NIHON KOHDEN CO/ADR (NHNKY), Insmed (INSM) and Acadia Healthcare (ACHC). View all competitors.

What other stocks do shareholders of Surgery Partners own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surgery Partners investors own include Verizon Communications (VZ), Allena Pharmaceuticals (ALNA), Bank of America (BAC), Netflix (NFLX), NVIDIA (NVDA), Ring Energy (REI), Ring Energy (REI), Advanced Micro Devices (AMD), Alteryx (AYX) and Carnival (CCL).

Who are Surgery Partners' key executives?

Surgery Partners' management team includes the following people:

Mr. Wayne Scott DeVeydt, CEO & Director (Age 49)
Mr. Thomas Francis Cowhey, Exec. VP, CFO & Principal Accounting Officer (Age 47)
Ms. Jennifer B. Baldock, Exec. VP & Chief Legal Officer (Age 48)
Dr. Angela Justice Ph.D., Exec. VP & Chief HR Officer (Age 46)
Mr. George M. Goodwin, Pres of American Group (Age 58)

What is Surgery Partners' stock symbol?

Surgery Partners trades on the NASDAQ under the ticker symbol "SGRY."

Who are Surgery Partners' major shareholders?

Surgery Partners' stock is owned by many different institutional and retail investors. Top institutional shareholders include Clearbridge Investments LLC (6.98%), BlackRock Inc. (3.29%), Centerbridge Partners L.P. (2.05%), JPMorgan Chase & Co. (1.62%), State Street Corp (0.92%) and Nuveen Asset Management LLC (0.46%). Company insiders that own Surgery Partners stock include Adam T Feinstein, Brandan Lingle, Jason Eric Evans and Teresa Deluca. View institutional ownership trends for Surgery Partners.

Which major investors are selling Surgery Partners stock?

SGRY stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., BlackRock Inc., Invesco Ltd., Clearbridge Investments LLC, Eaton Vance Management, State Street Corp, UBS Group AG, and Parametric Portfolio Associates LLC. View insider buying and selling activity for Surgery Partners.

Which major investors are buying Surgery Partners stock?

SGRY stock was acquired by a variety of institutional investors in the last quarter, including Centerbridge Partners L.P., JPMorgan Chase & Co., Assenagon Asset Management S.A., Voce Capital Management LLC, Nuveen Asset Management LLC, Two Sigma Investments LP, Victory Capital Management Inc., and Victory Capital Management Inc.. Company insiders that have bought Surgery Partners stock in the last two years include Jason Eric Evans, and Teresa Deluca. View insider buying and selling activity for Surgery Partners.

How do I buy shares of Surgery Partners?

Shares of SGRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Surgery Partners' stock price today?

One share of SGRY stock can currently be purchased for approximately $14.97.

How big of a company is Surgery Partners?

Surgery Partners has a market capitalization of $756.28 million and generates $1.83 billion in revenue each year. The company earns $-74,800,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. Surgery Partners employs 9,600 workers across the globe.

What is Surgery Partners' official website?

The official website for Surgery Partners is www.surgerypartners.com.

How can I contact Surgery Partners?

Surgery Partners' mailing address is 310 Seven Springs Way Suite 500, Brentwood TN, 37027. The company can be reached via phone at 615-234-5900 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff